FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer.
Not Applicable
Recruiting
- Conditions
- Esophageal cancer
- Registration Number
- JPRN-UMIN000002249
- Lead Sponsor
- Osaka Medical Center for Cancer and Cardiovascular Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Esophageal cancer spreading to pharynx or stomach. 2)Simultaneous double cancers. 3)Previous radiotherapy against cancer of thoracic cavity. 4)Uncontrollable complicating disease. 5)Interstitial pneumonia, fibroid lung. 6)History of collagen disease. 7)Psychosis. 8)Active infection which should be treated. 9)HBs antigen positive. HCV positive, TPHA positive, HIV positive 10)Women during pregnancy or breast-feeding. Men expecting to have a child.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method An association between FDG-PET finding during induction chemotherapy and the efficacy of chemoradiotherapy (CR or Non-CR).
- Secondary Outcome Measures
Name Time Method An association between FDG-PET finding during induction chemotherapy and overall survival. An association between FDP-PET finding during induction chemotherapy and disease-free survival. Safety. Optimal cut off value to predict CR Adverse event.